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revealed the absence of a significant association. The multi-
variate analysis of factors associated with a high BMI ( ≥ 30) in 
vitiligo patients showed a significant association between a 
high BMI and a sudden onset of vitiligo ( p = 0.021; OR = 3.83; 
95% CI 1.22–11.99) and the presence of inflammation and 
pruritus ( p = 0.031; OR = 3.26; 95% CI 1.11–9.57). No signifi-
cant association was observed in the analysis of factors as-
sociated with a low BMI ( ≤ 18.5) in vitiligo patients.  Conclu-
sion: In this study, vitiligo did not appear to be associated 
with a high BMI; obesity might not be a risk factor for vitiligo, 
in contrast to most autoimmune diseases which are signifi-
cantly associated with obesity.  © 2017 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Vitiligo is an acquired, depigmenting skin disorder 
characterized by the appearance of well-delineated, white 
macules on the skin due to the selective disappearance of 
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 Abstract 
 Objective: The purpose of this study was to investigate the 
relationship between vitiligo and body mass index (BMI) to 
assess the possible association between vitiligo and obesity. 
 Subjects and Methods: This was a case-control study on a 
total of 400 participants, i.e., 200 patients with vitiligo and 
200 healthy volunteers. Medical assessments were per-
formed by dermatologists using the modified Vitiligo Euro-
pean Task Force form. The height and weight of all of the 
participants were measured and used to calculate the BMI. 
Data were analyzed using multivariate logistic regression 
models. Adjustment for age and gender was carried out pre-
liminarily in the case-control analysis, whereas a forward 
stepwise selection algorithm was used to assess which inde-
pendent factors were associated with a BMI  ≥ 30 or a BMI 
 ≤ 18.5.  Results: Comparison of the vitiligo and control groups 
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 Significance of the Study 
 • In this study, vitiligo did not appear to be associated with a high body mass index, in contrast to most 
other autoimmune diseases. This lack of an association could be due to a high expression of p53 and a 
high concentration of transforming growth factor-β in vitiligo patients. Hence, in these patients, vit-
iligo could not lead to obesity.  
Th is is an Open Access article licensed under the Creative Commons 
Attribution-NonCommercial-4.0 International License (CC BY-NC) 
(http://www.karger.com/Services/OpenAccessLicense), applicable to
the online version of the article only. Usage and distribution for com-
mercial purposes requires written permission. Do
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functional melanocytes in the epidermis  [1] . Vitiligo af-
fects people of all ages and both sexes equally, with a prev-
alence of approximately 0.5% of the world population  [2] . 
Currently, vitiligo is considered a multifactorial disease 
with the specific involvement of autoimmunity, and thus 
vitiligo is regarded mainly as an autoimmune dermatosis 
 [3, 4] .
 The association between many autoimmune or in-
flammatory diseases and obesity had been demonstrated 
 [5, 6] . Rheumatoid arthritis, multiple sclerosis, systemic 
lupus erythematosus, systemic sclerosis, psoriasis, and 
autoimmune thyroid diseases are some of the disorders 
linked to obesity and they can also be associated with vit-
iligo  [5–9] .
 In obese people, fat cells produce high levels of leptin, 
a cytokine-like hormone that mediates the autocrine 
production of a wide variety of mediators including the 
proinflammatory cytokines tumor necrosis factor-α and 
interleukin-6 which contribute to creating a chronic in-
flammatory state capable of increasing the risk of 
autoimmune diseases  [10–13] . 
 In vitiligo, a significantly high expression of proin-
flammatory cytokines has been reported in lesional and 
perilesional skin. These are thought to be essential regula-
tors of melanocyte dysfunction and death. Contradictory 
results have been observed at a systemic level  [14–17] . 
Recently, elevated serum interleukin-17A, transforming 
growth factor-β1, and interleukin-21 levels have been 
identified at a systemic level in vitiligo patients  [18] .
 Karadag et al.  [19] showed that patients with vitiligo 
have a higher insulin resistance, a higher LDL/HDL ratio, 
and a higher systolic blood pressure. A recent report pro-
vided information on the reduction of some cardiovascu-
lar risk factors in patients with vitiligo. However, the re-
lationship between vitiligo and cardiovascular disease is 
not yet clear and no association between vitiligo and obe-
sity has ever been documented in a case-control study 
 [20] .
 The purpose of this study was to investigate the rela-
tionship between vitiligo and body mass index (BMI) to 
assess the possible association between vitiligo and obe-
sity.
 Subjects and Methods 
 A case-control study was performed at our specialized vitiligo 
outpatient service in Florence, Italy, during a 3-year period (March 
2012 to March 2015). A total of 400 Caucasian participants were 
included in this study, i.e., 200 patients with vitiligo and 200 
healthy volunteers. Of the 200 vitiligo patients, 92 were males and 
108 females, with ages ranging between 14 and 75 years. In doubt-
ful cases, a histological examination was performed to confirm the 
diagnosis. This study was conducted according to the principles of 
the Declaration of Helsinki, and written informed consent was ob-
tained from each patient for retrospective data collection. The 
medical assessment involved natural and Wood’s light examina-
tions consistent with the modified Vitiligo European Task Force 
form  [21] . Based on the Vitiligo European Task Force, a patient’s 
palm corresponding to 1% of body surface area was used to calcu-
late the total vitiligo extension  [22] . Exclusion criteria were seg-
mental vitiligo, doubtful diagnosis of vitiligo with no histological 
evidence, and no written informed consent. 
 The control group included 200 healthy volunteers (92 males 
and 108 females, aged between 17 and 76 years, with no history of 
dermatological or systemic disease and who were age and sex 
matched to the vitiligo patients. 
 The height and weight of all of the participants were measured 
and used to calculate the BMI (weight in kg divided by height in m 
squared [kg/m 2 ]). All of the participants were measured for height 
and weight and the BMI was calculated. BMI was taken as an index 
of obesity (BMI  ≥ 30 was the obesity marker and BMI  ≤ 18.5 was 
the underweight marker) and analyzed its possible relationship 
with the following clinical features of vitiligo: age at onset, vitiligo 
onset, modality of onset, growth of lesions, disease activity, total 
disease extension, Koebner’s phenomenon, and inflammation/
pruritus.
 A personal history of cardiovascular disease, cancer, autoim-
mune disease (discoid lupus erythematosus, alopecia areata, auto-
immune thyroiditis and/or gastritis, celiac disease, type 1 diabetes, 
Addison’s disease, and scleroderma) and psoriasis were all evalu-
ated. In addition, corticosteroid therapy, immunosuppressive 
therapy, and smoking habit were assessed. All of these data were 
obtained from paper and computerized medical records. 
 Statistical Analysis 
 Data were analyzed using multivariate logistic regression mod-
els. Adjustment for age (in quintiles) and gender was carried out 
preliminarily in the case-control analysis, whereas a forward step-
wise selection algorithm was then used to assess which indepen-
dent factors were associated with a BMI  ≥ 30 or a BMI  ≤ 18.5. The 
effect of selected factors was expressed in terms of OR with 95% CI 
and  p values.  p < 0.05 was considered statistically significant.
 Results 
 The general data for the cases and controls are summa-
rized in Appendix 1. The mean (±SD) and median age of 
the patients was 43.7 ± 16 and 45 years, respectively, and 
that of the controls was 44.3 ± 16.1 and 48.0 years, respec-
tively. Comparison of the vitiligo and control groups re-
vealed the absence of a significant association ( Table 1 ). A 
crude analysis of the factors associated with a high BMI 
( ≥ 30, obese) in vitiligo patients had a highlighted signifi-
cant association between a high BMI and sudden onset of 
vitiligo (appearance of all of the patches present at the time 
of the visit in <1 month) ( p = 0.028), the presence of in-
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flammation and pruritus in vitiligo lesions ( p = 0.037), and 
a personal history of cardiovascular disease ( p = 0.003) 
( Table 2 ). Multivariate analysis revealed a significant as-
sociation between a high BMI and sudden onset of vitiligo 
( p = 0.021; OR = 3.83; 95% CI 1.22–11.99) and the pres-
ence of inflammation and pruritus in vitiligo lesions ( p = 
0.031; OR = 3.26; 95% CI 1.11–9.57).
 No significant association was observed in the analysis 
of factors associated with a low BMI ( ≤ 18.5) in vitiligo 
patients ( Table 3 ). 
 Discussion 
 In this study, the high BMI was significantly associated 
with the sudden onset of vitiligo, inflammation, and pru-
ritus. Obesity is a proinflammatory condition in which 
hypertrophic adipocytes and adipose tissue-resident cells 
contribute to increase circulating levels of proinflamma-
tory cytokines  [23] . Leptin plays a pivotal role that can 
reduce the function and expansion of regulatory T cells 
and thereby amplifies inflammatory processes through 
the recruitment of CD8+ Th1 lymphocytes, mast cells, 
and macrophages and stimulates the release of proin-
flammatory cytokines and interleukin-2  [6] . Therefore, 
this chronic low-grade systemic inflammation can ex-
plain the association between a high BMI and the pres-
ence of inflammation/pruritus in vitiligo macules and 
possibly also the sudden onset of the disease.
 However, vitiligo did not seem to be associated with 
a high BMI, in contrast to most autoimmune diseases 
which are significantly associated with obesity  [6] . In-
creasing evidence suggests that the p53 tumor suppres-
sor protein which also has important regulatory func-
tions in cell growth/differentiation and metabolism is 
overexpressed in both lesional and nonlesional epider-
mis of patients with vitiligo  [24–26] . A recent in vivo 
study showed that p53 exerts a suppressive effect on 
white adipocyte differentiation in both mouse and hu-
man cells, suggesting that this protein has a potential 
protective effect against diet-induced obesity  [27] . The 
same study highlighted how p53 is implicated in proper 
brown adipose tissue differentiation which seemingly is 
protective against obesity  [27] . Thus, it is conceivable 
that in vitiligo patients p53 is overexpressed in adipose 
tissue as well as in the skin, explaining our results at least 
in part.
 An additional explanation of our results may be that 
in vitiligo there is a high systemic concentration of trans-
forming growth factor-β, which is known to be a potent 
 Table 1.  Case-control analysis
Vitiligo
(n = 200)
Control
 (n = 200)
p
value
n %  n %
Age, years 43.7 16.1 44.4 16.2
<35 65 32.5 61 30.5 0.544
35 – 49 53 26.5 63 31.5
50+ 82 41.0 76 38.0
Sex
Female 108 54.0 108 54.0 1
Male 92 46.0 92 46.0
BMI 23.8 3.5 23.6 4.3
≤18.5 29 14.5 33 16.5 0.667
18.6 – 29.9 153 76.5 154 77.0
≥30.0 18 9.0 13 6.5
Type of vitiligo onset
Early (age <18 years) 49 24.6 – – –
Late (>18 years) 150 75.4 – –
Speed of vitiligo onset
Sudden 83 42.3 – – –
Gradual 113 57.7 – –
Growth of vitiligo lesions
Absent 12 6.1 – – –
Slow 145 73.6 – –
Rapid 40 20.3 – –
Inflammation/pruritus
No 147 75.4 – – –
Yes 48 24.6 – –
Total vitiligo extension, % 7.6 16.7
<1.0 50 29.1 – – –
1.0 – 4.9 71 41.3 – –
≥5.0 51 29.7 – –
Disease activity
Active 104 53.6 – – –
Borderline 34 17.5 – –
Stable 56 28.9 – –
Koebner’s phenomenon
No 99 51.6 – – –
Yes 93 48.4 – –
Personal history of cardiovascular disease
No 176 88.0 164 82.0 0.193
Yes 24 12.0 36 18.0
Personal history of cancer
No 191 96.0 184 92.0 0.295
Yes 8 4.0 16 8.0
Personal history of autoimmune disease
No 165 82.5 194 97.0 0.101
Yes 35 17.5 6 3.0
Personal history of psoriasis
No 190 95.0 189 94.5 0.823
Yes 10 5.0 11 5.5
Smoker
No 108 60.0 142 71.0 0.224
Yes 72 40.0 58 29.0
Corticosteroid therapy
No 198 99.0 195 97.5 0.449
Yes 2 1.0 5 2.5
Immunosuppressive therapy
No 200 100.0 197 98.5 0.248
Yes 0 0.0 3 1.5
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 Table 2.  Crude analysis of factors associated with a high BMI (≥30) 
in vitiligo patients
N  BMI ≥30 p 
value n %
Age
<35 years 126 4 3.2 0.055
35 – 49 years 116 10 8.6
50+ years 158 17 10.8
Sex
Female 216 11 5.1 0.031
Male 184 20 10.9
Type of vitiligo onset
Early (age <18 years) 49 2 4.1 0.251
Late (age >18 years) 150 16 10.7
Speed of vitiligo onset
Sudden 83 12 14.5 0.028
Gradual 113 6 5.3
Growth of vitiligo lesions
Absent 12 0 0.0 0.746
Slow 145 15 10.3
Rapid 40 3 7.5
Inflammation/pruritus
No 147 9 6.1 0.037
Yes 48 8 16.7
Total vitiligo extension
<1.0% 50 4 8.0 1
1.0 – 4.9% 71 6 8.5
≥5.0% 51 5 9.8
Disease activity
Active 104 11 10.6 0.456
Borderline 34 1 2.9
Stable 56 5 8.9
Koebner’s phenomenon
No 99 9 9.1 0.695
Yes 93 7 7.5
Personal history of cardiovascular disease
No 340 20 5.9 0.003
Yes 60 11 18.3
Personal history of cancer
No 375 30 8.0 0.240
Yes 24 0 0.0
Personal history of autoimmune disease
No 359 30 8.4 0.348
Yes 41 1 2.4
Personal history of psoriasis
No 379 29 7.7 0.673
Yes 21 2 9.5
Smoker
No 250 16 6.4 0.210
Yes 130 13 10.0
Corticosteroid therapy
No 393 31 7.9 1
Yes 7 0 0.0
Immunosuppressive therapy
No 397 30 7.6 0.215
Yes 3 1 33.3
 Table 3.  Analysis of factors associated with a low BMI (≤18.5) in 
vitiligo patients
N  BMI <20 p
value n %
Age
<35 years 126 29 23.0 <0.001
35 – 49 years 116 23 19.8
50+ years 158 10 6.3
Sex
Female 216 49 22.7 <0.001
Male 184 13 7.1
Type of vitiligo onset
Early (age <18 years) 49 12 24.5 0.023
Late (age >18 years) 150 17 11.3
Speed of vitiligo onset
Sudden 83 11 13.3 0.602
Gradual 113 18 15.9
Growth of vitiligo lesions
Absent 12 2 16.7 0.639
Slow 145 23 15.9
Rapid 40 4 10.0
Inflammation/pruritus
No 147 25 17.0 0.143
Yes 48 4 8.3
Total vitiligo extension
<1.0% 50 8 16.0 0.254
1.0 – 4.9% 71 13 18.3
≥5.0% 51 4 7.8
Disease activity
Active 104 16 15.4 0.843
Borderline 34 4 11.8
Stable 56 9 16.1
Koebner phenomenon
No 99 13 13.1 0.556
Yes 93 15 16.1
Personal history of cardiovascular disease
No 340 59 17.4 0.015
Yes 60 3 5.0
Personal history of cancer
No 375 59 15.7 1
Yes 24 3 12.5
Personal history of autoimmune disease
No 359 54 15.0 0.454
Yes 41 8 19.5
Personal history of psoriasis
No 379 59 15.6 1
Yes 21 3 14.3
Smoker
No 250 40 16.0 0.969
Yes 130 21 16.2
Corticosteroid therapy
No 393 60 15.3 0.297
Yes 7 2 28.6
Immunosuppressive therapy
No 397 62 15.6 1
Yes 3 0 0.0
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inhibitor of white adipose tissue differentiation  [18, 28, 
29] . 
 Thus, it is conceivable that the high expression of p53 
and the high concentration of transforming growth 
factor-β can contribute to the absence of obesity in our 
patients, as opposed to other autoimmune diseases.
 A possible limitation of this study was noninvestiga-
tion of p53 and transforming growth factor-β, which 
could have affected the findings. 
 Conclusion 
 In this study, in contrast with most autoimmune dis-
eases which are significantly associated with obesity, vit-
iligo did not appear to be related to a high BMI. There-
fore, neither a high BMI nor obesity represents a feature 
of vitiligo in these patients and this seems to be an un-
usual autoimmune disease.
 Appendix 1 
 General characteristics of the case and control groups. 
Characteristic Vitiligo
(n = 200)
Control
(n = 200)
Gender
Female 108 108
Male 92 92
Age range 14 – 75 17 – 76 
Type of onset of vitiligo
Early (age <18 years) 49 (24.6%)
Late (age >18 years) 150 (75.4%)
Speed of vitiligo onset
Sudden 83 (42.3%)
Gradual 113 (57.7%)
Growth of vitiligo lesions
Absent 12 (6.1%)
Slow 145 (73.6%)
Rapid 40 (20.3%)
Inflammation/pruritus
No 147 (75.4%)
Yes 48 (24.6%)
Disease activity
Active 104 (53.6%)
Borderline 34 (17.5%)
Stable 56 (28.9%)
Total vitiligo extension
<1% 50 (29.1%)
1 – 4.9% 71 (41.3%)
≥5% 51 (29.7%)
Characteristic Vitiligo
(n = 200)
Control
(n = 200)
Koebner’s phenomenon
No 99 (51.6%)
Yes 93 (48.4%)
Personal history of cardiovascular disease
No 176 (88.0%) 164 (82.0%)
Yes 24 (12.0%) 36 (18.0%)
Personal history of autoimmune disease
No 165 (82.5%) 194 (97.0%)
Yes 35 (17.5%) 6 (3.0%)
Personal history of cancer
No 191 (96.0%) 184 (92.0%)
Si 8 (4.0%) 16 (8.0%)
Personal history of psoriasis
No 190 (95.0%) 189 (94.5%)
Yes 10 (5.0%) 11 (5.5%)
Corticosteroid therapy
No 198 (99.0%) 195 (97.5%)
Yes 2 (1.0%) 5 (2.5%)
Immunosuppressive therapy
No 200 (100.0%) 197 (98.5%)
Yes 0 (0.0%) 3 (1.5%)
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